Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.

ABSTRACT:

Objective

To describe the real-world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migraine prevention in Canada.

Background

The effectiveness of prophylactic migraine treatments is often undermined by poor treatment persistence. In clinical trials, erenumab has demonstrated efficacy and tolerability as a preventive treatment, but less is known about the longer term treatment persistence with erenumab.

Methods

This is a real-world retrospective cohort study where a descriptive analysis of secondary patient data was conducted. Enrollment and prescription data were extracted from a patient support program for a

SUBMITTER: Gladstone J 

PROVIDER: S-EPMC9298790 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature